(Total Views: 397)
Posted On: 09/14/2023 12:03:32 PM
Post# of 148908
BMY halts its NASH drug program.
That's really the extent of what's said in this article, but here's the link, if you want to give Adam Feuerstein some ad revenue.
https://endpts.com/bristol-myers-cuts-mid-sta...-programs/
Quote:
The New Jersey pharma company axed an siRNA for NASH, known as HSP47, which it licensed from Nitto Denko for $100 million upfront in 2016. Bristol Myers completed a Phase II study in 2019 investigating the therapy in patients with advanced liver fibrosis, or scar tissue buildup, after they were cured of hepatitis C. It had tested two different doses versus placebo in 61 patients, but both doses failed to make a difference in liver scarring compared to placebo, according to results in the federal clinical trials database.
That's really the extent of what's said in this article, but here's the link, if you want to give Adam Feuerstein some ad revenue.
https://endpts.com/bristol-myers-cuts-mid-sta...-programs/
(3)
(0)Scroll down for more posts ▼
